NSE: KIMS · 4 November 2026
- Krishna Institute of Medical Sciences Ltd. (KIMS) advanced by 1.38% today, closing at ₹740.55 compared to its previous close of ₹730.50. The stock traded within a day's range of ₹726.50 and ₹746.80 after opening slightly lower at ₹728.40.
- Saveera Institute of Medical Sciences Private Limited, a subsidiary operating KIMS Saveera Hospital in Anantapur, expanded its bed capacity from 250 to 500 beds. The newly inaugurated facilities include an oncology block equipped with an HD-LINAC, digital PET-CT, and brachytherapy, alongside a dedicated mother and child block with specialized neonatal care.
- Trading volume was 1.12 times the 20-day average daily volume.
Why is Krishna Institute of Medical Sciences share price rising on 4 November 2026?
Krishna Institute of Medical Sciences Ltd. (KIMS) advanced by 1.38% today, closing at ₹740.55 compared to its previous close of ₹730.50. The stock traded within a day's range of ₹726.50 and ₹746.80 after opening slightly lower at ₹728.40.
The broader market and sectoral backdrop provided positive momentum, as the Nifty benchmark rose 0.63% and the Nifty Pharma sector index added 0.42%. KIMS outperformed both broader and sectoral indices, extending its short-term recovery with a 5.10% gain over the past 5 trading days and a 6.80% gain over the past 20 trading days.
While no single specific company event was announced today, recent corporate developments include the expansion of KIMS Saveera Hospital in Anantapur from 250 to 500 beds on November 1, 2026, alongside recent strategic investments in Sangli and Kakinada healthcare entities. Additionally, the company scheduled its Q2FY27 financial results and an investor conference call for November 5, 2026, which may have influenced investor sentiment in the lead-up.
4.63 lakh shares traded by 4 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 4.12 lakh shares (1.12 times). The five-day average daily volume was 4.05 lakh shares. Separately, the NSE report for 4 November 2026 showed 3.01 lakh shares delivered, representing 64.98% of that day’s traded volume. The same report recorded 26,053 trades.
KIMS shares moved higher by 1.38% on above-average cash volume, outperforming both the Nifty and the Nifty Pharma index. The price action aligns with ongoing positive sentiment from recent hospital expansions and strategic acquisitions, alongside anticipation surrounding upcoming quarterly financial results and management discussions.
Latest Company Developments
Saveera Institute of Medical Sciences Private Limited, a subsidiary operating KIMS Saveera Hospital in Anantapur, expanded its bed capacity from 250 to 500 beds. The newly inaugurated facilities include an oncology block equipped with an HD-LINAC, digital PET-CT, and brachytherapy, alongside a dedicated mother and child block with specialized neonatal care.
This expansion strengthens the company's healthcare infrastructure and enhances access to advanced tertiary and quaternary care in the Rayalaseema region of Andhra Pradesh.
The company entered into definitive agreements to acquire a 51% equity stake in Sarvottam Health Care Private Limited, which operates a 183-bed hospital in Kakinada under the brand name Trust Multi Speciality Hospital, for a cash consideration of up to ₹79.50 crore based on a BDO Valuation Advisory LLP report.
It represents a strategic investment to expand KIMS' footprint in the East Godavari district and consolidate its operational presence in Andhra Pradesh.
KIMS entered into definitive agreements to acquire a 5.82% stake in Ushahkal Abhinav Specialty Hospital LLP in Sangli, Maharashtra, for an aggregate cash consideration of up to ₹15.00 crore by way of primary infusion.
The investment gives KIMS exposure to a 316-bed quaternary care facility with expansion potential to over 500 beds in Maharashtra.
The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.
allotment of 7702182 fully convertible warrants securities pursuant to Preferential Issue.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 28.21% on 30 September 2026. This compares with 28.52% on 30 June 2026, a change of -0.31 percentage points.
The filing reported 31 MF/UTI holders.
What to Watch Next
- Upcoming declaration of standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026.
- Scheduled conference call with analysts and investors hosted by IIFL Capital on November 5, 2026.
- Operational progress and integration updates regarding the newly expanded 500-bed facility at KIMS Saveera Hospital, Anantapur.
- Execution and completion timelines for the recently announced acquisitions of Sarvottam Health Care in Kakinada and Ushahkal Abhinav Specialty Hospital in Sangli.
More Krishna Institute of Medical Sciences news and dated analysis →
Frequently Asked Questions
What is the latest Krishna Institute of Medical Sciences company news?
Saveera Institute of Medical Sciences Private Limited, a subsidiary operating KIMS Saveera Hospital in Anantapur, expanded its bed capacity from 250 to 500 beds. The newly inaugurated facilities include an oncology block equipped with an HD-LINAC, digital PET-CT, and brachytherapy, alongside a dedicated mother and child block with specialized neonatal care.
How strong was Krishna Institute of Medical Sciences’s trading volume?
4.63 lakh shares traded, 1.12 times the 20-day average daily volume. The price and volume data are dated 4 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.